Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Exelixis’ Late-Stage Melanoma Combination Falls Short in Phase III Trial

Shares of Exelixis fell after the company disclosed in a U.S. SEC filing that a Phase III melanoma trial failed to hit endpoints.

Read More »

Five-Year Survival Observed In Longest Follow-Up Of Advanced Melanoma Patients Treated With Opdivo-Yervoy Combination

Bristol-Myers Squibb Company announced updated results from studies evaluating Opdivo (nivolumab) and Yervoy (ipilimumab), alone or in combination, in patients with advanced or metastatic melanoma.

Read More »

Array melanoma drugs show significant survival vs Roche drug in study

A combination of experimental drugs from Array BioPharma Inc. kept patients with advanced melanoma associated with a common gene mutation alive for nearly three years and twice as long as a rival Roche Holding AG medicine, according to data from a late-stage study.

Read More »

Combo therapy for melanoma gets priority review

The U.S. FDA granted priority review for Novartis’ Tafinlar in combination with Mekinist for treating some patients with advanced melanoma.

Read More »

Incyte Discloses Promising New Data in Combo Drug Trial With Merck & Co.’s Keytruda

Incyte Corporation will have an abstract published at the European Society for Medical Oncology (ESMO) meeting in early September with new and updated data from its ongoing Phase I/II trial of epacadostat in combination with Merck & Co.’s Keytruda in advanced melanoma.

Read More »

Bristol-Myers, Daiichi Sankyo to test Opdivo combo for cancers

Bristol-Myers Squibb Co. and Daiichi Sankyo said they were evaluating a combination of Bristol-Myers’ immuno-oncology drug, Opdivo with the Japanese company’s experimental drug in patients with breast and bladder cancers.

Read More »

Immunotherapy combo extends melanoma survival

Patients with advanced melanoma who received Bristol-Myers Squibb’s immunotherapies Opdivo and Yervoy had improved overall survival versus those on Yervoy alone.

Read More »

Bristol-Myers’ Opdivo extends survival in head and neck cancer – study

The cancer immunotherapy drug helped advanced head and neck cancer patients with a dismal prognosis live longer than other standard treatments, according to late-stage study data.

Read More »

Merck immunotherapy Keytruda shows promise in multiple myeloma trial

Merck & Co’s immunotherapy Keytruda led to a high response rate for patients with the blood cancer multiple myeloma when added to standard therapy in a small, early stage trial, according to data presented on Monday. The Phase I study tested Keytruda in combination with Celgene’s Revlimid and the corticosteroid dexamethasone in patients whose disease […]

Read More »

FDA approves new Bristol-Myers treatment for multiple myeloma

The U.S. Food and Drug Administration said on Monday it had approved a drug to be sold by Bristol-Myers Squibb Co as a treatment for a form of blood cancer. The FDA said it approved the treatment, Empliciti, to be used in multiple myeloma patients in combination with Celgene Corp’s Revlimid and common anti-inflammatory drug […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!

Subscribe

Ad Right Bottom